Sterling Capital Management’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADCT
ACM
OM
Sterling Capital Management's ADCT Position: Q3 2026 in Review
Sterling Capital Management increased its ADC Therapeutics (ADCT) stake by 33% in Q3 2026, buying an estimated $690 and bringing the position to 2,392 shares worth $2.92K. The position accounts for ﹤0.01% of the portfolio, ranked #3069.
Sterling Capital Management first reported a position in ADCT in Q3 2024 and has held it in 9 quarters since. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.
- Sterling Capital Management held 2,392 shares of ADC Therapeutics worth $2.92K as of Q3 2026.
- Sterling Capital Management bought 590 ADC Therapeutics shares in Q3 2026, an estimated $690.
- ADC Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3069 holding.
- Sterling Capital Management first reported a position in ADC Therapeutics in Q3 2024 and has held it in 9 quarters since.
- 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.